Delving into the Latest Updates on CH505TF gp120(NIAID) with Synapse

Overview

Basic Info

Drug Type

Prophylactic vaccine

Synonyms-

Target-

Action

stimulants

Mechanism

Immunostimulants

Therapeutic Areas

Immune System DiseasesInfectious DiseasesUrogenital Diseases

Active Indication-

Inactive Indication

HIV Infections

Originator Organization

National Institute of Allergy & Infectious Diseases

Active Organization-

Inactive Organization

National Institute of Allergy & Infectious Diseases

License Organization-

Drug Highest PhasePendingPhase 1

First Approval Date-

Regulation-

Login to view timeline

Author: Fong, Youyi ; Jacobsen, Thomas ; Paez, Carmen A ; Church, L W Preston ; Kublin, James G ; Martik, Diana ; Furch, Briana D ; Corey, Lawrence ; Robinson, Samuel T ; Lu, Yiwen ; Maughan, Maureen ; Kelley, Colleen F ; Montefiori, David C ; Tomaras, Georgia D ; Heptinstall, Jack R ; Zhang, Lu ; Yacovone, Margaret ; Wilson, Gregory J

AbstractUtilizing transiently transfected cell lines could significantly reduce manufacturing timelines for protein subunit vaccines. This trial compared safety and immunogenicity of human immunodeficiency virus (HIV) envelope CH505TF gp120 vaccines produced by upstream stable and transient transfection (each admixed with GLA-SE adjuvant, a TL4 agonist). Both vaccines were safe and well tolerated. Serum IgG binding antibody response rates 2 weeks after final injection were 92% in the stable group and 93% in the transient group (P = 1.000). Neutralization response rates against CH505.w4.3 were also equivalent (92% vs 100%, P = .291). These data support transient transfection as an available tool for accelerating HIV vaccine testing and iteration.Clinical Trials Registration. NCT03856996.

100 Deals associated with CH505TF gp120(NIAID)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
HIV Infections	Phase 1	United States	National Institute of Allergy & Infectious Diseases	23 May 2019

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03856996 (CTgov)	Phase 1	HIV Infections	30	GLA-SE+CH505TF gp120 (Group 1: Vaccine)	kwmeceauhw(zduslrezhu) = agbhlocmic nvdkmkdopt (kselejotjo, wwjdcccbhv - bpmgnlbznz) View more	-	11 Jul 2022
				GLA-SE+CH505TF (Group 2: Vaccine)	kwmeceauhw(zduslrezhu) = qqsuktsegi nvdkmkdopt (kselejotjo, bopwwemjlh - nluzhkixkh) View more